Imagen de Portada

COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis

COVID-19 convalescent plasma (CCP) obtained from recently recovered people is safe and effective against SARS-CoV-2. Currently available CCP is a “hybrid” product with antibodies from individuals who had both infection and vaccination (vaccine-boosted CCP). B-cell depleted patients are at risk of no...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zaremba, Solomiia (Autor) , Focosi, Daniele (Autor) , Pruter, Wyatt W. (Autor) , Franchini, Massimo (Autor) , Collantes Hoyos, Diana B. (Autor) , Cruciani, Mario (Autor) , Miller, Alex J. (Autor) , Ripoll, Juan G. (Autor) , Casadevall, Arturo (Autor) , Tulledge-Scheitel, Sidna M. (Autor) , Rufer, Nathalie (Autor) , Hueso, Thomas (Autor) , Juskewitch, Justin E. (Autor) , van Buskirk, Camille M. (Autor) , Ioannou, Petros (Autor) , Lanza, Francesco (Autor) , Razonable, Raymund R. (Autor) , Magyari, Ferenc (Autor) , Pinczés, László Imre (Autor) , Ganesh, Ravindra (Autor) , Denkinger, Claudia M. (Autor) , Hurt, Ryan T. (Autor) , Janssen, Maike (Autor) , Stubbs, James R. (Autor) , Müller-Tidow, Carsten (Autor) , Winters, Jeffrey L. (Autor) , Holm, Karin (Autor) , Parikh, Sameer A. (Autor) , Simeunovic, Gordana (Autor) , Kay, Neil E. (Autor) , Rijnders, Bart J. (Autor) , Wright, Scott R. (Autor) , Issa, Nahema (Autor) , Chaussade, Hélène (Autor) , Carter, Rickey E. (Autor) , Schroeder, Darrell R. (Autor) , Senefeld, Jonathon W. (Autor) , Joyner, Michael J. (Autor)
Formato: Article (Journal)
Lenguaje:inglés
Publicado: 17 October 2025
In: Frontiers in medicine
Year: 2025, Volumen: 12, Pages: 1-13
ISSN:2296-858X
DOI:10.3389/fmed.2025.1658593
Acceso en línea:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3389/fmed.2025.1658593
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1658593/full
Enlace del recurso
Notas de Autor:Solomiia Zaremba, Daniele Focosi, Wyatt W. Pruter, Massimo Franchini, Diana B. Collantes Hoyos, Mario Cruciani, Alex J. Miller, Juan G. Ripoll, Arturo Casadevall, Sidna M. Tulledge-Scheitel, Nathalie Rufer, Thomas Hueso, Justin E. Juskewitch, Camille M. van Buskirk, Petros Ioannou, Francesco Lanza, Raymund R. Razonable, Ferenc Magyari, László Imre Pinczés, Ravindra Ganesh, Claudia M. Denkinger, Ryan T. Hurt, Maike Janssen, James R. Stubbs, Carsten Müller-Tidow, Jeffrey L. Winters, Karin Holm, Sameer A. Parikh, Gordana Simeunovic, Neil E. Kay, Bart J. Rijnders, Scott R. Wright, Nahema Issa, Hélène Chaussade, Rickey E. Carter, Darrell R. Schroeder, Jonathon W. Senefeld, Michael J. Joyner
Descripción
Sumario:COVID-19 convalescent plasma (CCP) obtained from recently recovered people is safe and effective against SARS-CoV-2. Currently available CCP is a “hybrid” product with antibodies from individuals who had both infection and vaccination (vaccine-boosted CCP). B-cell depleted patients are at risk of not producing antibodies after either infection or vaccination, hence conceivably among those who would benefit the most from CCP. We thus conducted a systematic review and individual participant data meta-analysis to assess characteristics associated with 60-day survival in B-cell depleted patients transfused with CCP. The protocol was registered with PROSPERO (CRD42024516513) on March 1st, 2024. The last search was on April 2nd, 2024, and included all studies using CCP in B-cell depleted patients. Whenever not available, we requested individual participant data from corresponding authors of eligible studies. Risk of bias was assessed using Joanna Briggs Institute Critical Appraisal Tools. Data were analyzed using conditional logistic regression. The overall 60-day survival rate was 86.5% in our cohort of 570 patients (85 included studies). After controlling for age, sex, calendar year of infection and World Health Organization (WHO) disease severity, we found a significant association between 60-day survival and transfusion of vaccine-boosted CCP (OR = 9.49; 95% CI 2.01-44.82; p = 0.005). Overall survival in our cohort of B-cell depleted patients was consistent with prior meta-analysis of randomized controlled trials on survival of immunocompromised patient transfused with CCP (~84%). A novel finding from this analysis is that vaccine-boosted CCP is associated with a high survival benefit.
Notas:Gesehen am 26.05.2026
Online veröffentlicht: 17. Oktober 2025
Descripción Física:Online Resource
ISSN:2296-858X
DOI:10.3389/fmed.2025.1658593

Ejemplares similares